TaiMed Biologics - Asset Resilience Ratio
TaiMed Biologics (4147) has an Asset Resilience Ratio of 18.13% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 4147 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how TaiMed Biologics's Asset Resilience Ratio has changed over time. See TaiMed Biologics net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down TaiMed Biologics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 4147 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$872.35 Million | 18.13% |
| Total Liquid Assets | NT$872.35 Million | 18.13% |
Asset Resilience Insights
- Good Liquidity Position: TaiMed Biologics maintains a healthy 18.13% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
TaiMed Biologics Industry Peers by Asset Resilience Ratio
Compare TaiMed Biologics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for TaiMed Biologics (2013–2025)
The table below shows the annual Asset Resilience Ratio data for TaiMed Biologics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.13% | NT$872.35 Million ≈ $27.48 Million |
NT$4.81 Billion ≈ $151.56 Million |
-3.36pp |
| 2024-12-31 | 21.50% | NT$1.07 Billion ≈ $33.86 Million |
NT$5.00 Billion ≈ $157.50 Million |
+11.27pp |
| 2023-12-31 | 10.22% | NT$398.13 Million ≈ $12.54 Million |
NT$3.89 Billion ≈ $122.68 Million |
+1.17pp |
| 2022-12-31 | 9.05% | NT$371.29 Million ≈ $11.70 Million |
NT$4.10 Billion ≈ $129.21 Million |
+0.18pp |
| 2021-12-31 | 8.88% | NT$409.27 Million ≈ $12.89 Million |
NT$4.61 Billion ≈ $145.26 Million |
-3.28pp |
| 2020-12-31 | 12.15% | NT$631.57 Million ≈ $19.90 Million |
NT$5.20 Billion ≈ $163.71 Million |
-7.33pp |
| 2019-12-31 | 19.48% | NT$921.55 Million ≈ $29.03 Million |
NT$4.73 Billion ≈ $149.04 Million |
-10.28pp |
| 2018-12-31 | 29.76% | NT$1.43 Billion ≈ $44.92 Million |
NT$4.79 Billion ≈ $150.94 Million |
-13.20pp |
| 2017-12-31 | 42.97% | NT$1.93 Billion ≈ $60.95 Million |
NT$4.50 Billion ≈ $141.87 Million |
-7.68pp |
| 2016-12-31 | 50.65% | NT$2.43 Billion ≈ $76.62 Million |
NT$4.80 Billion ≈ $151.28 Million |
-3.59pp |
| 2015-12-31 | 54.24% | NT$2.67 Billion ≈ $84.19 Million |
NT$4.93 Billion ≈ $155.21 Million |
-5.04pp |
| 2014-12-31 | 59.28% | NT$1.11 Billion ≈ $35.13 Million |
NT$1.88 Billion ≈ $59.25 Million |
+20.21pp |
| 2013-12-31 | 39.07% | NT$279.25 Million ≈ $8.80 Million |
NT$714.72 Million ≈ $22.52 Million |
-- |
About TaiMed Biologics
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinica… Read more